Fluidiconic Biotechnology
- Medical device or technology
- CMO, CRO
Fluidiconic Biotech is dedicated to advancing precision oncology through innovative tumor-on-a-chip technology. Our proprietary MedSelect platform enables ex vivo drug evaluation using patient-derived tumor cells, accurately simulating the heterogeneous tumor environment to predict therapeutic efficacy and resistance. By integrating dynamic circulation, immune cell interactions, physiological gradients, desmoplasia, angiogenesis, and drug concentration dynamics over time, MedSelect provides pharmaceutical companies and CROs with a powerful preclinical tool to accelerate drug development and optimize treatment strategies.
Address
HsinchuTaiwan
Taiwan
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}